BioCryst Pharmaceuticals, Inc. (BCRX)
|52 Week Range||7.61-19.99|
|1y Target Est||-|
|DCF Unlevered||BCRX DCF ->|
|DCF Levered||BCRX LDCF ->|
|Debt / Equity||-330.20%||Strong Sell|
Upgrades & Downgrades
Latest BCRX news
Pharmaceutical Stock Sinks on Sales Forecast
9 January 2023
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock is sinking today, down 11.6% at $10.45 at last glance, after the company's sales forecast for its skin disease drug, Orladeyo, came in below estimates.
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
4 January 2023
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Co...
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
20 December 2022
As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' Orladeyo is enjoying strong sales reactions in its second year of launch. Coupled with ongoing global market expansions and on to...
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
16 December 2022
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
BCRX Stock Sinks as BioCryst Discontinues Drug Development
15 December 2022
BioCryst Pharmaceuticals (NASDAQ: BCRX ) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development alongside BCX10013 as a Factor D inhibitor.
BioCryst to discontinue development of drug
15 December 2022
Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysma...
BioCryst to Present at JMP Securities Hematology & Oncology Summit
5 December 2022
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology &...
3 Biotechnology stocks under 10 dollars to buy now
26 November 2022
Here are three inexpensive biotech stocks with a bright future ahead of them.
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
1 November 2022
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief...